Medtronic (NYSE:MDT) announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand coverage for CGMs.
CMS’ expanded coverage covers all types of CGMs (continuous glucose monitors), including adjunctive and non-adjunctive CGMs, and it notably covers CGMs that integrate with Medtronic insulin pumps.
According to a news release, the proposed rule was finalized yesterday (December 21) and will be effective starting 60 days after official publication.
The expanded coverage also ensures the continuity of therapy for users on certain Medtronic insulin pump systems transitioning into Medicare, including Medtronic’s hybrid closed-loop systems that automatically adjust insulin delivery based on readings from the integrated CGM.
Medtronic said it intends to continue to offer its CGM access discount to all Medicare customers until the ruling goes into effect.
“We commend CMS for taking action to help more people with diabetes and empowering them to choose the therapies that best meet their diabetes management needs,” VP of Health Economics, Reimbursement & Government Affairs for Medtronic’s Diabetes Business Jeff Farkas said in the release. “This is a very important benefit expansion for our customers who have experienced significant clinical and quality of life benefits from their integrated Medtronic insulin pump systems and are now able to receive coverage for all components of their system on Medicare.”